Prostate Cancer Update 2

SELECT PUBLICATIONS

Bolla M et al. Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): A phase III randomised trial. Lancet 2002;360(9327):103-6. Abstract

Carducci MA et al. What is more exciting? The activity of docetaxel in early prostate cancer or the successful collaboration between urologists and medical oncologists to complete a study in early prostate cancer? J Clin Oncol 2005;23:3304-7. No abstract available

D’Amico AV et al. 6-month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: A randomized controlled trial. JAMA 2004;292(7):821-7. Abstract

Dearnaley DP et al. Early efficacy and late toxicity of escalated-over-standard-dose conformal radiotherapy with neo-adjuvant androgen suppression for men with localized prostate cancer: First results of MRC RT01 trial (ISRCTN47772397). Proc ASCO Prostate Cancer Symposium 2007;Abstract 295.

Glode LM et al. SWOG 9921 — A phase III multi-institutional trial of adjuvant therapy for high risk prostate cancer after radical prostatectomy. Proc ASCO Prostate Cancer Symposium 2007; Abstract 349.

Gomella LG. Addressing the needs of the high-risk prostate cancer patient. Rev Urol 2005;7(Suppl 5):S18-28. Abstract

Jang TL et al. Visits to urologists and radiation oncologists prior to treatment decision making for clinically localized prostate cancer (LCaP). Proc ASCO 2007; Abstract 6506.

Katz MS et al. Predictors of biochemical outcome with salvage conformal radiotherapy after radical prostatectomy for prostate cancer. J Clin Oncol 2003;21(3):483-9. Abstract

King CR et al. Radiotherapy after radical prostatectomy: Does transient androgen suppression improve outcomes? Int J Rad Oncol Biol Phys 2004;59(2):341-7. Abstract

Loblaw DA et al. Initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer: 2006 update of an American Society of Clinical Oncology practice guideline. J Clin Oncol 2007;25(12):1596-605. Abstract

Messing EM et al. Immediate versus deferred androgen deprivation treatment in patients with node-positive prostate cancer after radical prostatectomy and pelvic lymphadenectomy. Lancet Oncol 2006;7(6):472-9. Abstract

Petrylak DP et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004;351(15):1513-20. Abstract

Prostate Cancer Trialists’ Collaborative Group. Maximum androgen blockade in advanced prostate cancer: An overview of the randomised trials. Lancet 2000;355(9214):1491-8. Abstract

Sands ME et al. Influence of radiotherapy on node-positive prostate cancer treated with androgen ablation. Int J Radiat Oncol Biol Phys 1995;31(1):13-9. Abstract

Spiotto MT et al. Radiotherapy after prostatectomy: Improved biochemical relapse-free survival with whole pelvic compared with prostate bed only for high-risk patients. Int J Radiat Oncol Biol Phys 2007;69(1):54-61. Abstract

Stephenson AJ et al. Predicting the outcome of salvage radiation therapy for recurrent prostate cancer after radical prostatectomy. J Clin Oncol 2007;25(15):2035-41. Abstract

Stephenson AJ et al. Postoperative nomogram predicting the 10-year probability of prostate cancer recurrence after radical prostatectomy. J Clin Oncol 2005;23(28):7005-12. Abstract

Tannock IF et al; TAX 327 Investigators. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004;351(15):1502-12. Abstract

Taplin ME et al. Docetaxel, estramustine, and 15-month androgen deprivation for men with prostate-specific antigen progression after definitive local therapy for prostate cancer. J Clin Oncol 2006;24(34):5408-13. Abstract

Wong Y et al. Role of androgen deprivation therapy (ADT) for node-positive prostate cancer. Proc ASCO Prostate Cancer Symposium 2007;Abstract 193.

Zaider M et al. Methodology for biologically-based treatment planning for combined low-dose-rate (permanent implant) and high-dose-rate (fractionated) treatment of prostate cancer. Int J Radiat Oncol Biol Phys 2005;61(3):702-13. Abstract

Zeitman AL et al. Comparison of conventional-dose vs high-dose conformal radiation therapy in clinically localized adenocarcinoma of the prostate: A randomized controlled trial. JAMA 2005;294(10):1233-9. Abstract

Zelefsky MJ et al. Clinical experience with intensity modulated radiation therapy (IMRT) in prostate cancer. Radiother Oncol 2000;55(3):241-9. Abstract